Aurora Advances Global Medical Cannabis Portfolio with New Product Launches Across Key International Markets

NASDAQ | TSX: ACB Q1 launches reinforce Aurora's medical‑first strategy, expanding access to high‑quality products across multiple formats Scaled launches across Canada, Europe and Australia support growing demand in regulated international medical markets Continued focus on quality, patient needs and reliable global supply through Aurora's extensive GMP‑certified network EDMONTON, AB, April 28, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian‑based leading global medical cannabis company, is significantly expanding its global medical cannabis portfolio, with new product launches rolling out across Canada, Europe and Australia. The company continues to shape the global cannabis landscape by introducing new products and formats around the world.